EP2309269B1 - Zusammensetzungen und verfahren zur detektion von hiv-1/hiv-2 infektion - Google Patents

Zusammensetzungen und verfahren zur detektion von hiv-1/hiv-2 infektion Download PDF

Info

Publication number
EP2309269B1
EP2309269B1 EP10174056.1A EP10174056A EP2309269B1 EP 2309269 B1 EP2309269 B1 EP 2309269B1 EP 10174056 A EP10174056 A EP 10174056A EP 2309269 B1 EP2309269 B1 EP 2309269B1
Authority
EP
European Patent Office
Prior art keywords
hiv
vax
nhlbi
peptide
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP10174056.1A
Other languages
English (en)
French (fr)
Other versions
EP2309269A1 (de
Inventor
Hana Golding
Surender Khurana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
US Government
Original Assignee
US Department of Health and Human Services
US Government
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, US Government filed Critical US Department of Health and Human Services
Publication of EP2309269A1 publication Critical patent/EP2309269A1/de
Application granted granted Critical
Publication of EP2309269B1 publication Critical patent/EP2309269B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/161—HIV-1 ; HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p7, p6, p66/68, p51/52, p31/34, p32, p40
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/162—HIV-1, HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Definitions

  • This invention relates to compositions and methods for the detection of immunodeficiency virus infection, especially human immunodeficiency virus-1 (HIV-1) infection.
  • the invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.
  • HIV human immunodeficiency virus
  • HIV-1 is the causative agent of acquired immune deficiency syndrome (AIDS) and related disorders ( Gallo, R.C. et al. (1983) "Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS),” Science 220(4599):865-7 ; Barre-Sinoussi, F. et al.
  • HIV human immunodeficiency virus
  • Prime-boost strategies are under way to optimize cellular and humoral immune responses. Consequently, vaccine recipients' sera are often reactive in licensed HIV serodetection assays, generating patterns indistinguishable from HIV-infected individuals ( Ackers, M.L. et al. (2003) "HUMAN IMMUNODEFICIENCY VIRUS (HIV) SEROPOSITIVITY AMONG UNINFECTED HIV VACCINE RECIPIENTS," J Infect Dis 187:879-986 ; Pitisuttithum, P. et al.
  • HIV-2 also known as the West African AIDS Virus
  • West Africa also known as the West African AIDS Virus
  • infected individuals are found primarily in West Africa ( Smith, R.S. et al. (1990) "SYNTHETIC PEPTIDE ASSAYS To DETECT HUMAN IMMUNODEFICIENCY VIRUS TYPES 1 AND 2 IN SEROPOSITIVE INDIVIDUALS," Arch Pathol Lab Med. 114(3):254-258 ; Baillou, A. et al.
  • HIV acts to compromise the immune system of infected individuals by targeting and infecting the CD-4 + T lymphocytes that would otherwise be the major proponents of the recipient's cellular immune system response
  • T4 T4
  • ANTIGEN Is AN ESSENTIAL COMPONENT OF THE RECEPTOR FOR THE AIDS RETROVIRUS Nature 312: 767-768
  • Infection of cells by HIV -1 requires membrane attachment of the virion and subsequent fusion of the viral and cellular membranes.
  • the fusion process is mediated by the viral outer envelope glycoprotein complex (gp120/gp41) and target cell receptors ( McGaughey, G.B. et al. (2004) “PROGRESS TOWARDS THE DEVELOPMENT OF A HIV-1 GP41-DIRECTED VACCINE," Curr HIV Res. 2(2):193-204 ).
  • the envelope glycoprotein is synthesized as a precursor protein (gp160) that is proteolytically cleaved into two non-covalently associated protein subunits, a surface subunit (gp120) and a transmembrane subunit (gp41).
  • the gp120 envelope protein is responsible for binding to the CD4 cell-surface receptor and a chemokine co-receptor, CCR5 or CXCR4. Following receptor binding, the membrane-anchored gp41 mediates fusion of the viral and target cell membranes.
  • the gp41 ectodomain contains a hydrophobic, glycine-rich fusion peptide (amino acids 512-527) at the amino terminus that is essential for membrane fusion (numbering based on HXB2 gp160 variant as described in Chan, D.C. et al. (1997) "CORE STRUCTURE OF GP41 FROM THE HIV ENVELOPE GLYCOPROTEIN,” Cell 89(2):263-273 ).
  • Two 4,3 hydrophobic repeat regions following the fusion peptide are defined by a heptad repeat (abcdefg)n, where the residues occupying the a and d positions are predominantly hydrophobic.
  • the two heptad repeat regions are referred to as the N36 (residues 546-581) and C34 (residues 628-661) peptides.
  • a loop region containing a disulfide linkage separates the two heptad repeat regions.
  • the region of the gp41 ectodomain proximal to the viral membrane is abundant in the amino acid tryptophan (amino acids 665 ⁇ 683) and has been shown to be critical for the membrane fusion mechanism of HIV-1.
  • Gp41 exists in two distinct conformations, a native or non-fusogenic state and a fusion-active state (fusogenic state) ( McGaughey, G.B. et al. (2004) "PROGRESS TOWARDS THE DEVELOPMENT OF A HIV-1 GP41-DIRECTED VACCINE," Curr HIV Res. 2(2):193-204 ).
  • gp41 exists in the native state with the N-terminal fusion peptide largely inaccessible.
  • gp41 undergoes a series of conformational changes leading to the fusion-active conformation ( Chan, D.C. et al.
  • the detection of HIV infection may be accomplished by either identifying viral proteins in the sera of infected individuals, by identifying viral nucleic acids in plasma or cells, or by detecting host antibodies that are produced by such individuals in response to viral infection. Strategies involving the detection of viral proteins are complicated by the low levels of such proteins during HIV infection, and by high assay cost. Thus, the detection of HIV infection is typically accomplished by detecting host anti-HIV antibodies ( Manocha, M. et al.
  • HIV human immunodeficiency virus
  • Second generation assays used purified viral proteins obtained from infected cells to bind, and identify, such antibodies. However, since diagnostically relevant viral proteins, such as those encoded by the HIV-1 env gene were difficult to obtain in large quantities, “second generation”assays were soon developed that employed recombinantly produced HIV antigens.
  • Synthetic peptide antigens coupled with ELISA offers several potential advantages over other types of assays, potentially increasing the sensitivity and specificity of the assay, decreasing its cost, and providing a relatively simple format that would be suitable for testing sizeable number of samples in any laboratory ( Manocha, M. et al. (2003) "COMPARING MODIFIED AND PLAIN PEPTIDE LINKED ENZYME IMMUNOSORBENT ASSAY (ELISA) FOR DETECTION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 (HIV-1) AND TYPE-2 (HIV-2) ANTIBODIES,” Immunol Lett. 85(3):275-278 ).
  • Suitable synthetic peptides comprise short protein sequences that can be recognized by antibodies that have been elicited through an individual's exposure to the intact viral protein ( Alcaro, M.C. et al. (2003) “SYNTHETIC PEPTIDES IN THE DIAGNOSIS OF HIV INFECTION,” Curr Protein Pept Sci. 4(4):285-290 ).
  • such peptides must possess the following characteristics: (1) an ability to detect an antibody response in all HIV-infected individuals; (2) an ability to detect an antibody response as early as possible after infection; and (3) an ability to maintain detection of antibody response over all stages of the disease ( Dopel, S.H. et al.
  • HIV-1 p24 (gag) protein, gp160/120 (env) protein and gp41 (env envelope transmembrane protein) have been proposed as having serodiagnostic importance, and as being a potential source of suitable peptides ( Alcaro, M.C. et al. (2003) “SYNTHETIC PEPTIDES IN THE DIAGNOSIS OF HIV INFECTION,” Curr Protein Pept Sci. 4(4):285-290 ).
  • This invention relates to compositions and methods for the detection of immunodeficiency virus infection, especially human immunodeficiency virus-1 (HIV-1) Infection.
  • the invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV antibodies.
  • the invention also concerns peptide antigens that may be used in anti-HIV vaccine compositions.
  • HIV-1 prophylactic vaccines currently under development are complex products containing multiple viral genes or proteins.
  • vaccine recipients' sera are expected to be identified as reactive in HIV-1 or HIV-2 or both HIV 1 & 2 seroconversion detection assays and thus to produce patterns indistinguishable form sera obtained from infected individuals. This will have a negative impact on future clinical trials of prophylactic HIV vaccines that require early detection of breakthrough infections. It will also exclude all vaccinees from the pool of potential blood donors, and may contribute to other social harms.
  • the present inventors have identified new HIV-1 epitopes which are: (a) broadly reactive with early serum samples from individuals infected with HIV virus strains from all clades; (b) do not contain protective antibody or cytotoxic epitopes; and (c) can be easily removed from current and future HIV-1 candidates.
  • Gene-Fragment Phage Display libraries constructed from whole HIV-1 genome are used to identify such epitopes and to construct differential enzyme-immunoassays that are capable of distinguishing reactivities from infection-induced anti-HIV antibodies from vaccine-induced anti-HIV reactivities.
  • the invention relates to a method for detecting the presence, or measuring the concentration, of an anti-HIV-1 antibody in a biological sample of a human, wherein said method comprises conducting an immunoassay comprising the steps of: (a) contacting said biological sample with a peptide having an epitope that is recognized by said anti-HIV-1 antibody, said contacting being under conditions sufficient to permit said anti-HIV-1 antibody if present in said sample to bind to said epitope and form a peptide-anti-HIV-1 antibody complex; (b) contacting said formed peptide-anti-HIV-1 antibody complex with an anti-HIV-1 antibody binding molecule, said contacting being under conditions sufficient to permit said anti-HIV-1 antibody binding molecule to bind to anti-HIV-1 antibody of said formed peptide-anti-HIV-1 antibody complex and form an extended complex; and (c) determining the presence of concentration of said anti-HIV-1 antibody in said biological sample by determining the presence or concentration of said formed extended complex; wherein said peptide
  • the invention relates to a peptide having the amino acid sequence of SEQ ID NO:50 or SEQ ID NO:55 .
  • the invention in another aspect, relates to an immunological complex comprising a peptide sequence selected from the group consisting of SEQ ID NOs:50-56 , said peptide bound to an anti-HIV-1 antibody, wherein said anti-HIV-1 antibody is additionally bound to an anti-HIV antibody binding molecule, wherein said peptide comprises an epitope that is recognized by said anti-HIV-1 antibody.
  • the invention relates to a kit for detecting the presence, or measuring the concentration, of an anti-HIV-1 antibody in a biological sample of a human
  • said kit comprises a hollow casing comprising a multilayer filter system, and first and second porous carriers, wherein said second porous carrier is in communication with said first porous carrier, and said first porous carrier is in communication with said multilayer filter system, a portion of which is accessible from said casing;
  • said first porous carrier contains a non-immobilized, labeled peptide which comprises at least one amino acid sequence selected from the group consisting of SEQ ID NOS:50-56 ; said amino acid sequence comprising an eopitope recognized by said anti-HIV-1 antibody;
  • said second porous carrier contains an immobilized, unlabeled antibody that binds to human IgG.
  • the present invention uses various peptide sequences as covered by the Claims.
  • the following figures refer to the peptides of the Claims and additional sequences. These additional sequences are included for comparative purposes only.
  • This invention relates to compositions and methods for the detection of immunodeficiency virus-1 (HIV-1) infection.
  • the invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.
  • HIV human immunodeficiency virus
  • the new generation of vaccine candidates are complex products, containing multiple HIV genes or proteins, using diverse delivery systems and new adjuvants. It is anticipated that within few years several vaccine candidates will progress into large scale efficacy trials, particularly in countries with high infection rates. It is hoped that the new generation vaccines will offer at least partial protection against new infections and possibly reduce viral loads and delay disease progression in infected vaccinated individuals. In order to achieve the statistical power needed to demonstrate partial efficacy, it will be necessary to recruit thousands of volunteers into future phase III HIV vaccine trials. Many of these volunteers will react positively in licensed HIV detection tests. Hence, further improvements in HIV diagnosis are urgently required.
  • HIV infection status One of the critical determinations during ongoing trials in high-risk populations is the HIV infection status of trial participants. Intercurrent infections must be detected as soon as possible in order to stop vaccination and monitor infected individuals for viral load, immune status, and disease progression. Treatment and public health measures depend on a timely diagnostic information.
  • vaccine trials are using an algorithm of HIV detection that incorporates antibody or antigen-based kits, followed by Western Blots and finally, confirmatory PCR based assays.
  • many of the vaccine trial participants irrespective of their HIV infection status, seroconvert in all licensed antibody detection kits, including the recently licensed rapid tests (( Ackers, M.L. et al.
  • HIV-1 vaccine candidates Due to increasing complexity of HIV-1 vaccine candidates, most vaccinees are expected to react positive in the licensed HIV-1 detection assays (EIA, rapid test, Western blots). There are several negative outcomes to the anticipated high prevalence of false-positives in the vaccinated individuals. These outcomes reflect the criticality of distinguishing between HIV infected recipients and individuals who have merely become seroconverted due to the administration of the vaccine:
  • the present invention addresses these concerns by providing new HIV-1 epitopes that will fulfill some, and more preferably all, of the following criteria:
  • a gene-fragment phage display library may be employed for this purpose.
  • a library is produced using limited DNase I digestion of HIV-1 or HIV-2 DNA ( Figure 1 ).
  • target DNA containing HIV-1 or HIV-2
  • the digestion products are fractionated, for example using gel electrophoresis.
  • the termini of the fractionated samples are preferably polished using T4 polymerase (see, e.g., Costa, G.L. et al.
  • the treated fragments are then preferably introduced into a phagemid or phage vectors (based on filamentous phages including M13, f1, etc.) operably linked to a displayed phage protein and are then amplified to produce a phage display library, each of whose members displays an HIV peptide sequence on its surface.
  • phagemid or phage vectors based on filamentous phages including M13, f1, etc.
  • phage display library each of whose members displays an HIV peptide sequence on its surface.
  • other libraries can be used including Ribosomal display, other viruses, and phages or bacterial cells or Yeast or other eukaryotic display systems for the same purpose.
  • Desired peptides are then identified, preferably by panning the library on immobilized serum antibodies from HIV-1-infected individual (early seroconversion) under conditions that permit the recovery of library members that bind strongly to the immobilized antibodies ( Figure 2 ). Preferably, this is accomplished by capturing library members whose arrayed HIV peptide binds to an immobilized anti-HIV antibody. After discarding unbound phagemids, the bound phagemids are eluted and recovered (eluted phagemids may be amplified to enhance their recovery).
  • Suitable members mapping to the HIV-1 GAG-p6, RT, IN, Vif, gp 120, gp41, and Nef genes can be identified in this manner.
  • members mapping to the gag, pol, Envelope and nef encoding regions of HIV are preferably conducted using panels of sequential sera from HIV-1 seroconvertors.
  • Figure 3 illustrates the relationship between the desired epitopes of the present invention, and those of vaccine candidates.
  • Epitopes mapping to the HIV-1 GAG-p6, gp41, Vif and Nef genes are believed to possess significant utility as diagnostic agents for the detection of anti-HIV antibodies, since, for gp41 and p6, there is >90% sequence conservation among HIV-1 clades.
  • gp41 and Gag-p6 peptides were recognized at high frequency (combined sensitivity of 99.1%) by serum/plasma of 1200 samples from seropositive individuals including early seroconvertors. The specificity is currently at 98.2% for p6 and 100% for gp41 (1000 negative samples).
  • the Gag-p6 and gp41 peptides do not contain important known neutralizing antibody or CTL epitopes and they are not present in most HIV vaccines. Identified peptides are suitable for use in HIV diagnostic kits.
  • epitopes used in the present invention are those specified in the Claims.
  • the remaining epitopes are maintained merely for comparative purposes.
  • the identified gp41 epitopes ( SEQ ID NO:50 and SEQ ID NO:51 ) differ in sequence from the sequences of previously identified gp41 peptides. Aligning SEQ ID NO:50 and SEQ ID NO:51 against the HIV-1 gp41 sequence ( SEQ ID NO:56; NC_001802) yields the following comparison (sites of SEQ ID NO:56 that are not conserved are shown in single-underline (if conserved in either SEQ ID NO:50 or SEQ ID NO:51 ) or in double-underline (if not conserved in either SEQ ID NO:50 or SEQ ID NO:51) ) ( Table 5 ): Table 5 SEQ ID NO Description Sequence 50 Isolated Epitope LI AA RIVELLG HSSLKGL RRGWEALKYLWNLLQTW G QELKNSA I SL 51 Isolated Epitope LIVTRIVELLG ⁇ RRGWEALKYWWNLLQTWSQELKNSAV N L 56 Gp41 LI VT RI
  • both SEQ ID NO:50 and SEQ ID NO:51 differ in sequence from the sequence of the corresponding native HIV-1 gp41 gene product ( SEQ ID NO:56 ).
  • An alignment of these sequences with a series of gp41 consensus sequences indicates that SEQ ID NO:50 and SEQ ID NO:51 differ in sequence from the consensus sequences.
  • a blast search of SEQ ID NO:50 failed to identify any identical gene sequences.
  • a blast search of SEQ ID NO:51 identified two sequences that were 100% identical to SEQ ID NO:51 (Sequence AAC28452 ( Fang, H. et al. (1995) J. Virol. 69 (1), 75-81 ; Sequence P04582 ( Ratner, L. et al. (1985) Nature 313:277-284 (1985 ). Of the sequences that differed from SEQ ID NO:51 by one amino acid residue, a substitution of L38 ⁇ N38 was common (see, e.g., Sequence CAD10927 ( Zheng, N.N. et al., Direct submission ). SEQ ID NOs:50, 53 and 55 are particularly preferred as gp41 epitope sequences.
  • HIV 1 gp41 consensus epitopes are shown in Table 7 below: Table 7 SEQ ID No. Description Sequence 66 CON_OF_CONS 67 Mgroup.anc 68 CONSENSUS_A1 69 A1.anc 70 CONSENSUS_A2 71 CONSENSUS_B 72 B.anc 73 CONSENSUS_C 74 C.anc 75 CONSENSUS_D 76 CONSENSUS_F1 77 CONSENSUS_F2 78 CONSENSUS_G 79 CONSENSUS_H 80 CONSENSUS_01_AE 81 CONSENSUS_02_AG 82 CONSENSUS_03_AB 83 CONSENSUS_04_CPX 84 CONSENSUS_06_CPX 85 CONSENSUS_08_BC 86 CONSENSUS_10_CD 87 CONSENSUS_11_CPX 88 CONSENSUS_12_BF 89 CONSENSUS_14_BG
  • HIV-1 gp41 epitope sequences SEQ ID NO:50 or SEQ ID NO:55
  • any of SEQ ID NOS:49-56 are useful as diagnostic agents in accordance with the principles of the present invention.
  • diagnostic assays are contemplated wherein an HIV-1 epitope sets are employed wherein the peptide epitope sets consist essentially of HIV-1 gp41 terminal region epitopes
  • HIV-1 gp41 terminal region epitopes refers to epitopes contained on amino acids 784-871 of Consensus aligned seq in Los Alamos database, or mutants or derivatives thereof.
  • an epitope set will consist essentially of gp41 when the peptide epitope set does not contain other epitopes that show significant reactivity (i.e. preferably less than 130% of background level, more preferably less than 120% of background level, and most preferably less than 110% of background level) with anti-HIV 1 antibodies.
  • Peptide molecules containing the epitopes of the invention may be prepared using virtually any art-known technique for the preparation of peptides.
  • the peptides may be prepared using conventional step-wise solution or solid phase peptide syntheses, or recombinant DNA techniques or proteolysis or modifications of purified viral proteins/peptides or recombinant proteins.
  • Peptides may be prepared using conventional step-wise solution or solid phase synthesis (see, e.g., Merrifield, R B. (1969) "SOLID-PHASE PEPTIDE SYNTHESIS,” Adv. Enzymol. Relat Areas Mol. Biol. 32:221-296 ; Fairwell, T. et al.
  • such peptides of the invention may be prepared by way of segment condensation, as described, for example, in Schnölzer, M. et al,. "CONSTRUCTING PROTEINS BY DOVETAILING UNPROTECTED SYNTHETIC PEPTIDES: BACKBONE-ENGINEERED HIV PROTEASE," Science. 1992 Apr 10;256(5054):221-5 ; Schnölzer, M., "IN SITU NEUTRALIZATION IN BOC-CHEMISTRY SOLID PHASE PEPTIDE SYNTHESIS. RAPID, HIGH YIELD ASSEMBLY OF DIFFICULT SEQUENCES," Int J Pept Protein Res.
  • Such assays of HIV will comprise enzyme immunosorbent assays (EIAs) that employ one or more of the above-described gp41 peptides, or fragments or variants thereof
  • 1, 2 or 3 such peptides are employed in such assays.
  • the selected peptides alone or in combination, can be used to differentiate between vaccine directed antibodies and breakthrough infection generated antibodies to assess the efficacy of vaccine clinical trials, or to monitor potential infections.
  • Fragments or variants of the peptides preferably comprise at least 10, 20 or 30 contiguous amino acids of the peptides and are at least 70%, preferably at least 75%, 80%, or 85%, more preferably at least 90%, and most preferably at least 95% homologous to the indicated peptides.
  • a preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence (i.e. homology), also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al., 1990, Comp. App. Biosci.6:237-245 .
  • a sequence alignment the query and subject sequences are both amino acid sequences.
  • the result of said global sequence alignment is in percent identity.
  • the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total residues of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment.
  • This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score.
  • This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.
  • a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity.
  • the deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus.
  • the 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%.
  • a 90 residue subject sequence is compared with a 100 residue query sequence.
  • deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query.
  • percent identity calculated by FASTDB is not manually corrected.
  • residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.
  • an epitope is a 2- or 3-dimensional region of an antigen that is recognized by and that specifically binds to an antibody.
  • an epitope and an antibody are said to be “specific” for one another, or to "recognize” one another, or to "bind” to one another if they are capable of immunospecific binding to one another.
  • any of a wide variety of assay formats may be used in accordance with the methods of the present invention. Such formats may be heterogeneous or homogeneous, sequential or simultaneous, competitive or noncompetitive.
  • U.S. Patent Nos. 5,563,036 ; 5,627,080 ; 5,633,141 ; 5,679,525 ; 5,691,147 ; 5,698,411 ; 5,747,352 ; 5,811,526 ; 5,851,778 ; and 5,976,822 illustrate several different assay formats and applications. Such assays can be formatted to be quantitative, to measure the concentration or amount of an anti-HIV antibody, or they may be formatted to be qualitative, to measure the presence or absence of an anti-HIV antibody.
  • Heterogeneous immunoassay techniques typically involve the use of a solid phase material to which the reaction product becomes bound, but may be adapted to involve the binding of non-immobilized antigens and antibodies (i.e., a solution-phase immunoassay).
  • the reaction product is separated from excess sample, assay reagents, and other substances by removing the solid phase from the reaction mixture (e.g., by washing).
  • One type of solid phase immunoassay that may be used in accordance with the present invention is a sandwich immunoassay. In the sandwich assay, the more analyte present in the sample, the greater the amount of label present on the solid phase. This type of assay format is generally preferred, especially for the visualization of low analyte concentrations, because the appearance of label on the solid phase is more readily detected.
  • a peptide of the present invention that is specifically reactive with an anti-HIV antibody is bound to a solid support (i.e., immobilized) and incubated in contact with the biological sample being tested for the presence of an anti-HIV antibody.
  • a blocking agent may be added to reduce non-specific binding.
  • the peptide may be incubated with the biological sample in an unbound state and then subsequently bound to the solid support (i.e., immobilizable).
  • the supports are then preferably extensively treated (e.g., by washing, etc.) to substantially remove non-HIV antibodies that may be present but that failed to bind to the bound peptide. In consequence of such treatment, an immune complex forms between the peptide and anti-HIV antibody.
  • a detectably labeled second antibody (capable of binding to the initial antibody (e.g., an anti-human IgG antibody)) is then preferably added and the support is incubated under conditions sufficient to permit the second antibody to bind to any anti-HIV antibody that may be present.
  • the support is then preferably extensively treated (e.g., by washing, etc.) to substantially remove any unbound second antibody. If anti-HIV antibody is present in the test sample, then the two antibodies will form an immune complex with the immobilized peptide (i.e., a second antibody/anti-HIV antibody/ immobilized peptide sandwich). In such an assay, the detection of second antibody bound to the support is indicative of anti-HIV antibody in the sample being tested.
  • the second antibody may be a natural immunoglobulin isolated from nonhuman species (e.g., anti-human IgG murine antibody, anti-human IgG goat antibody, anti-human IgM goat antibody, etc.), or it can be produced recombinantly or synthetically. It may be an intact immunoglobulin, or an immunoglobulin fragment (e.g., FAb, F[Ab] 2 , etc.).
  • binding molecules capable of binding to anti-HIV antibodies
  • the anti-HIV antibodies can be biotinylated and the second antibody can be replaced with labeled avidin or streptavidin.
  • a homogeneous assay format may alternatively be employed.
  • one component of the binding pair may still be immobilized; however, the presence of the second component of the binding pair is detected without a bound-free separation.
  • homogeneous optical methods are the EMIT method of Syva, Inc.
  • the binding assay of the present invention may be configured as a competitive assay.
  • a competitive assay the more anti-HIV antibody present in the test sample, the lower the amount of label present on the solid phase.
  • the competitive assay can be conducted by providing a defined amount of a labeled anti-HIV antibody and determining whether the fluid being tested contains anti-HIV antibody that would compete with the labeled antibody for binding to the support.
  • the amount of captured labeled antibody is inversely proportional to the amount of analyte present in the test sample.
  • Smith U.S. Patent No. 4,401,764
  • Clagett U.S. Patent No.
  • 4,746,631 describes an immunoassay method using a reaction chamber in which an analyte/ligand/marker conjugate is displaced from the reaction surface in the presence of test sample analyte and in which the displaced analyte/ligand/marker conjugate is immobilized at a second reaction site.
  • the conjugate includes biotin, bovine serum albumin, and synthetic peptides as the ligand component of the conjugate, and enzymes, chemiluminescent materials, enzyme inhibitors, and radionucleotides as the marker component of the conjugate.
  • 4,661,444 describes a competitive immunoassay using a conjugate of an anti-idiotype antibody and a second antibody, specific for a detectable label, in which the detectable response is inversely related to the presence of analyte in the sample.
  • Allen European Patent Appln. No. 177,191
  • a binding assay involving a conjugate of a ligand analog and a second reagent, such as fluorescein, in which the conjugate competes with the analyte (ligand) in binding to a labeled binding partner specific for the ligand, and in which the resultant labeled conjugate is then separated from the reaction mixture by means of solid phase carrying a binding partner for the second reagent.
  • This binding assay format combines the use of a competitive binding technique and a reverse sandwich assay configuration; i.e., the binding of conjugate to the labeled binding member prior to separating conjugate from the mixture by the binding of the conjugate to the solid phase.
  • the assay result is determined as in a conventional competitive assay in which the amount of label bound to the solid phase is inversely proportional to the amount of analyte in the test sample.
  • Chieregatt et al. (GB Patent No. 2,084,317 ) describe a similar assay format using an indirectly labeled binding partner specific for the analyte.
  • Mochida et al. U.S. Patent No.
  • At least one component of the assay reagents will preferably be labeled or otherwise detectable by the evolution or quenching of light.
  • Such component may be a second antibody, anti-HIV antibody, or the peptide that binds to the anti-HIV antibody, depending on the immunoassay format employed.
  • Radioisotopic-binding assay formats e.g., a radioimmunoassay, etc.
  • Enzymatic-binding assay formats employ an enzyme as a label; the signal is detectable by the evolution of color or light in the presence of a chromogenic or fluorogenic moiety.
  • Other labels such as paramagnetic labels, materials used as colored particles, latex particles, colloidal metals such as selenium and gold, and dye particles (see U.S. Patent Nos. 4,313,734 ; 4,373,932 , and 5,501,985 ) may also be employed.
  • enzymes especially alkaline phosphatase, ⁇ -galactosidase, horse radish peroxidase, or urease
  • EIA enzyme immunoassay
  • the presence of enzymatic labels may be detected through the use of chromogenic substrates (including those that evolve or adsorb fluorescent, UV, visible light, etc.) in response to catalysis by the enzyme label. More preferably, chemical labels may be employed (e.g., colloidal gold, latex bead labels, etc.). Detection of label can be accomplished using multiple detectors, multipass filters, gratings, or spectrally distinct fluors (see e.g., U.S. Patent No. 5,759,781 ), etc. It is particularly preferred to employ peroxidase as an enzyme label, especially in concert with the chromogenic substrate 3, 3', 5, 5'-tetramethylbenzidine (TMB), OPD, or ABTS.
  • TMB 5, 5'-tetramethylbenzidine
  • any of a wide variety of solid supports may be employed in the immunoassays of the present invention.
  • Suitable materials for the solid support are synthetics such as polystyrene, polyvinyl chloride, polyamide, or other synthetic polymers, natural polymers such as cellulose, as well as derivatized natural polymers such as cellulose acetate or nitrocellulose, and glass, especially glass fibers.
  • the support can take the form of spheres, rods, tubes, and microassay or microtiter plates. Sheet-like structures such as paper strips, small plates, and membranes are likewise suitable.
  • the surface of the carriers can be permeable and impermeable for aqueous solutions.
  • any fluidic biological sample e.g., tissue or biopsy extracts, extracts of feces, sputum, etc.
  • the biological sample being assayed will be serum or plasma.
  • Table 11 illustrates the variables that may be employed in an ELISA (BSA- bovine serum albumin; FBS- fetal bovine serum; HRP-horsradish peroxidase; AP- alkaline phosphatase; TMB- 3, 3', 5, 5'-tetramethylbenzidine; OPD - o-phenylenediamine dihydrochloride).
  • the ELISA employs a peptide for epitope presentation, 250 ng (for Env-gp41) coating, blocking by milk, a HRP-Anti-Human IgG + IgG-Fc as the 2 nd antibody (at a 10,000 fold dilution), and OPD as a substrate.
  • Buffers that may be employed include commonly used buffers such as PBS or Tris buffers, with or without Tween-20 or other detergents commonly used for immunoassays.
  • kits may comprise a carrier means being compartmentalized to receive in close confinement; one or more containers means vials, tubes and the like; each of the containers means comprising one of the separate elements to be used in the method.
  • one of the containers means may comprise a peptide of the present invention (for example, any of SEQ ID NOS 50-55 with or without the a peptide linker, e.g. a carboxy-terminal GGGC (SEQ ID NO:138) peptide linker) bound to a solid support.
  • a second container may comprise soluble, detectably labeled second antibody, preferably in lyophilized form, or in solution.
  • the kit may also contain one or more containers, each of which comprises a (different) predetermined amount of an anti-HIV antibody. These latter containers can be used to prepare a standard curve into which can be interpolated the results obtained from the sample containing the unknown amount of anti-HIV antibodies.
  • kits In using the kit, all the user need do is add to a container a premeasured amount of a sample suspected of containing a measurable yet unknown amount of anti-HIV antibody, a premeasured amount of support-bound peptide present in the first container, and a premeasured amount of the detectably labeled second antibody present in the second container.
  • an immune complex is formed (if the sample contained anti-HIV antibody) and is separated from the supernatant fluid, and the immune complex or the supernatant fluid are detected, as by radioactive counting, addition of an enzyme substrate, and color development, or by inclusion of a chemical label (e.g., colloidal gold, latex beads, etc.).
  • a chemical label e.g., colloidal gold, latex beads, etc.
  • the present invention particularly relates to the use of immunochromatographic assay formats to detect anti-HIV antibodies.
  • immunochromatographic assay format two contacting, but spatially distinct, porous carriers are employed.
  • the first such carrier will contain a non-immobilized, labeled peptide of the present invention and the second such carrier will contain an immobilized, but unlabeled antibody that binds to IgG (e.g., where human anti-HIV antibodies are being assayed, the unlabeled antibody may be an anti-human IgG antibody).
  • the device will comprise a hollow casing constructed of, for example, a plastic material, etc., in which the first carrier will communicate indirectly with the interior of the casing via a multilayer filter system that is accessible from the device (e.g., by protruding therefrom or by being incompletely covered by the device), such that a serum, plasma, or whole blood test sample can be applied directly to the filter system and will permeate therefrom into the first porous carrier.
  • a serum, plasma, or whole blood test sample can be applied directly to the filter system and will permeate therefrom into the first porous carrier.
  • the permeation of fluid containing anti-HIV antibodies will cause the non-immobilized labeled peptide of the first carrier to become bound to the migrating antibodies, and will then permeate into the second carrier.
  • the second carrier contains immobilized antibody that binds human IgG, any labeled peptide entering the second carrier will be entrapped therein. Detection of labeled peptide in the carrier containing the immobilized unlabeled antibody thus indicates that anti-HIV antibodies were present in the sample being evaluated.
  • the assay can be made quantitative by measuring the quantity of labeled peptide that becomes bound within the second porous carrier.
  • the present invention uses various peptides covered by the Claims.
  • the following examples refer to the peptides covered by the Claims and additional sequences that do not form part of the invention.
  • the additional sequences are included for comparative purpose only.
  • the library is subjected to panning on immobilized serum antibodies from IIIV-1-infected individual (early seroconversion). Phages that bind to the immobilized antibodies are retained, while non-binding, or weakly binding, phages are washed-off ( Figure 2 ).
  • DNA sequencing of the captured phages allows the mapping of the selected peptides to known HIV proteins. Initially, 11 "phagotopes" were selected and sequenced. They map to GAG-p6, RT, IN, Vif, gp120, gp41, and Nef. These sequences are produced as synthetic peptides.
  • the reactivities of the synthetic peptides are tested with early seroconversion samples from different countries and different clades (under standardized conditions).
  • Pre-clinical and clinical samples of immune sera from recent HIV vaccine candidates, likely to proceed to phase I/II/III trials, are screened in order to confirm and expand the above-described demonstration of the ability of the newly discovered HIV-1 epitopes, either alone or in combination, to react with high percentage of plasma from early seroconversion-patients.
  • Currently licensed EIA kits may be used for side-by-side analysis.
  • the selected peptides in combination can be used to differentiate between vaccine directed antibodies and breakthrough infection generated antibodies during HIV vaccine clinical trials.
  • ELISAs are characterized for the following sample types: normal (non-HIV infected) serum samples (for cut-off determination); confirmed HIV infected serum samples; seroconversion samples, serum samples from patients infected with different HIV-1 subtypes, randomly collected serum samples-blinded panel, vaccinated individual serum samples. ELISAs are also characterized for cross-reactivity with other pathogens including reteroviruses.
  • a peptide for epitope presentation a coating of 33ng (for GAG-p6) or 250 ng (for ENV-gp-41), blocking by 2% milk, a 1:100 serum/plasma dilution, a HRP-Anti-Human IgG -Fc as the 2 nd antibody (at 1:10,000 fold dilution), and OPD as substrate.
  • Buffers employed may be common buffers such as PBS or Tris buffer, with or without Tween-20 or other detergents commonly used for immunoassays. All incubations are done at room temperature for 1 hr each, except for blocking by milk, which is done for 2-3 hrs.
  • the peptides employed are the GAG-p6 (SEQ ID NO:3) and gp41 (SEQ ID NO:50 and SEQ ID NO:55)), alone and in combination. These assay conditions are employed in the ELISAs described in the examples provided below, unless otherwise indicated.
  • the average optical density (OD) was 0.005
  • the standard deviation (SD) was 0.0025
  • the actual cut-off used was 0.035.
  • the Specimen/Cut-Off Ratio is defined as the Absorbance of the Test Sample divided by the actual Cut-Off Value.
  • the sample is scored as positive for the presence of anti-HIV antibodies, and is termed "HIV positive.” If the Specimen/Cut-Off Ratio is less than 1, the sample is scored as negative for the presence of anti-HIV antibodies, and is termed "HIV negative.”
  • the Specimen/Cut-Off Ratio was determined for an HIV+ serum sample at times ranging from 0 to 40 days. The results of this experiment are shown in Table 12.
  • Abbott HIV1/2 is a licensed HIV serodetection kit. HIV Ag is a licensed kit to detect p24. Data relating to FDA licensed EIA Kits was generated by Boston Biomedica Inc (Gaithersburg, USA). Table 12 Sample I.D. Day Collected CBER p6 CBER gp41 Abbott HIV 1/2 Abbott HIV Ag FDA LIC.
  • the peptides and assays of the present invention are employed using the above-described ELISA conditions to detect HIV-1 infection in serum from seroconverted individuals.
  • the data from such assays is shown in Table 14.
  • Table 14 Sample ID ID Number Day Collected Specimen/Cut-Off Ratio p6 gp41 AUS-105 PS04017 0 0.51 3.97 8 0.56 5.41 29 0.7 12.33 56 0.87 16.24 168 0.88 25.93 259 2.69 29.32 AUS-107 PS01019 0 0.93 3.52 28 1.07 4.95 61 0.71 4.97 168 0.78 11.95 AUS-108 PS02016 0 1.73 0.42 12 2.64 0.45 31 1.24 0.99 66 3.06 4.82 192 0.73 7.89 269 0.77 19.35 AUS-113 PS01026 0 0.41 12.56 27 0.56 14.91 56 0.73 20.15 166 0.75 21.22 AUS-114 PS01029 0 2.77 7.4 7 2.12 7.22 28 2.86 7.41
  • the peptides and assays of the present invention are evaluated using the above-described ELISA conditions for cross-clade reactivity in their detection of HIV-1 infection.
  • the data from such assays is shown in Table 15.
  • Table 15 Sample I.D. HIV-1 Genotype p6 gp41 Origin of Sample Abbott HIV 1/2 FDA LIC. EIA KITS WWRB303 - 01 A 6.26 29.17 Ghana >15.9 4/4 WWRB303-02 A 18.44 0.53 Ghana >15.9 4/4 WWRB303-03 C 3.24 4.53 S. Africa >15.9 4/4 WWRB303 - 04 C 5.12 1.09 S.
  • the data demonstrates that the peptides and assays of the present invention exhibit broad cross-clade reactivity in their detection of HIV-1 infection.
  • the peptides and assays of the present invention are evaluated using the above-described ELISA conditions for their ability to detect HIV-1 infection using random serum samples from individuals infected with diverse HIV-1 clades.
  • the data from such assays is shown in Table 16.
  • the data shown in Table 16 indicates that the gag p6 epitope had an individual sensitivity of 83%, compared with 67% for the gp41 epitope. The use of both epitopes had an individual sensitivity of 82%. The overall sensitivity was 100%.
  • the data shows that peptides designed based on HIV-1 subtype consensus sequences with false negative serum could detect HIV infection.
  • the data shows that HIV-1 specific peptides individually or in combination are able to detect anti-HIV-1 antibodies in serum or plasma early after acute infection.
  • the assay specificity for the 1200 samples obtained from individuals infected with diverse HIV clades is found to be 98.2 % (For Consensus peptide GAG-p6) and 100 % (For Consensus peptide CON-Env2-gp41).
  • the cross clade combined reactivity is found to be 94.4 % sensitivity (B-subtype) and 99.1% (for Consensus peptides).
  • the peptides and assays of the present invention are able to detect HIV epitopes in serum samples infected with diverse HIV-1 subtypes.
  • Table 18 SAMPLE ID CBER p6 CBER Gp41 Subtype and Infection Status NHLBI-1 17.57 0.23 Brazil; clade B; LSI NHLBI-2 0.98 6.22 Brazil; clade B; LSI NHLBI-3 0.69 13.55 Brazil; clade B; LSI NHLBI-4 1.44 27.58 Brazil; clade B; LSI NHLBI-5 7.86 35.23 Brazil; clade B; LSI NHLBI-6 3.18 0.43 Brazil; clade B; LSI NHLBI-7 7.21 33.97 Brazil; clade B; LSI NHLBI-8 4.77 1.75 Brazil; clade B; LSI NHLBI-9 15.90 0.18 Brazil; clade B; LSI NHLBI-10 6.34 0.35 Brazil; clade B; LSI NHLBI-11 10.56 24.45 Brazil; clade B; LSI NHLBI-12 2.63 7.94 Brazil
  • Table 19 summarizes the ability of the HIV-SELECTEST to detect HIV-infected serum with diverse clades. Table 19 Summary of HIV-SELECTEST with I-IIV-Infected Serum Samples with Diverse Clades Subtype Number of Samples HIV-SELECTEST Reactive % Combined Sensitivity A 25 25 100 B 263 259 98.48 C 50 50 100 D 20 19 95 E 104 103 99.04 G 11 11 100 J 4 4 100 AG 150 150 100 AJ 7 7 100 F2, U, H, J/G Recombinants 9 9 100 CRF 21 21 100 Unknown Genotypes 589 585 99.32 Total No. Samples 1253 1243 99.2
  • the reactivity of CBER p6 and CBER p41 with RV124 vaccine trial samples were compared with the reactivity of the BioRad Kit with RV124 vaccine trial samples at 0 and 182 days post-vaccination.
  • the vaccination given in the RV124 vaccine trials was as follows: ALVAC-HIV (vCP205; gag-LAI + pro-LAI + gp120MN/gp41TM-LAI) with HIV-gp160 protein boost (gp120MN, gp41 LAI-2) (with Gag-p6) .
  • the results for individual samples are shown in Table Table 20 below. The results show substantially more false positive reactions using the BioRad kit versus the use of CBER p6 or CBER p41.
  • RV124-41 0.30 0.18 0.43 0.19 NEGATIVE 0.38 10.64 RV124-42 0.37 0.23 0.96 0.20 NEGATIVE 0.21 10.65 V124-43 0.53 0.21 0.50 0.24 NEGATIVE 0.26 0.14 RV1124-44 0.18 0.37 0.13 0.23 NEGATIVE 0.24 10.95 RV124-45 0.10 0.36 0.08 0.22 NEGATIVE 0.31 10.99 RV 124-46 0.20 0.18 0.15 0.10 NEGATIVE 0.41 10.13 RV124-47 0.41 0.20 0.99 0.17 NEGATIVE 0.35 10 .
  • RV124-48 0.32 0.19 0.75 0.17 NEGATIVE 0.33 10.40 RV 124-49 0.67 0.30 0.47 0.16 NEGATIVE 0.35 0.14 RV124-50 0.63 0.18 0.43 0.11 NEGATIVE 0.35 10.55 RV124-51 0.22 0.09 0.99 0.09 NEGATIVE 0.46 10.43 RV124-52 0.87 0.33 0.23 0.27 NEGATIVE 0.32 10.68 RV124-53 0.63 0.18 0.52 0.25 NEGATIVE 0.20 11.07 RV124-54 0.26 0.13 0.53 0.13 NEGATIVE 0.15 1.17 RV 124-55 0.27 0.14 0.27 0.12 NEGATIVE 0.16 0.19 RV124-56 0.85 0.11 0.98 0.20 NEGATIVE 0.15 10 .
  • the present invention provides a new HIV-1 detection assay, in which vaccine-generated antibodies will not cross-react, while seroconversion can be detected early post-infection.
  • the selection criteria for HIV sequences to be used in such an assay included epitopes that are: 1) not included in HIV vaccines, 2) recognized by antibodies early after HIV infection, and 3) highly conserved among HIV clades and subtypes.
  • HIV-SELECTEST is a new HIV enzyme-linked immunosorbent assay that could be implemented in clinical sites and blood collection centers worldwide, and serve as an important diagnostic tool in HIV vaccine trials.
  • Plasmid pNL4-3, containing the complete HIV-1 NL4-3 proviral DNA was obtained from the NIH AIDS Research and Reference Reagent Program (McKesson BioServices Corp., Rockville, MD).
  • Full length HIV-1 genome was PCR amplified from pNL4-3 DNA with the Expand long template polymerase preparation (Roche Diagnostics, Indianapolis, IN) and primers spanning the Lys t-RNA primer binding site (MSF12, ( SEQ ID NO:139 ) 5'- AAAAATCTCTAGCAGTGGCGCCCGAACAG- 3' ) and the poly-A signal region of 3'-LTR (MSR5, ( SEQ ID NO:140) 5'-AAGCACTCAAGGCAAGCTTTATTGAGGCT- 3'), which amplifies the entire HIV-1 genome except for 75 bp in the unique-5' (U5) region of the LTR.
  • the purified amplified DNA product was digested with DNase 1 using DNase shotgun cleavage kit (Novagen, Madison, WI), and fragments between 50 and 300 bp were isolated by preparative gel electrophoresis, treated with T4 DNA polymerase to generate blunt ends, and dephosphorylated using calf intestinal alkaline phosphatase (CIP) (Roche Diagnostics, Indianapolis, IN). DNA was again purified using nucleotide removal kit (Qiagen Inc, Valencia, CA) and was ligated in the presence of Srf I enzyme into the Sma I site of the M13 derived phage vector for expression as gIIIp fusion protein, followed by electroporation into E. coli TG1 cells.
  • DNase 1 DNase shotgun cleavage kit
  • CIP calf intestinal alkaline phosphatase
  • Tet-resistant transformants were harvested and expanded in liquid culture (2X-YT) at 37 °C.
  • the cell-free phage supernatant was isolated by centrifugation and phage titer was determined as Tet r transduction units.
  • Ninety six individual clones were isolated and DNA inserts were amplified by standard PCR and sequenced to determine the insert size distribution and library diversity.
  • PBST 20 mM PBS containing 0.1% Tween 20
  • DMEM containing 5% FBS blocking solution
  • VCSM13 pre-adsorbed HIV-1 human plasma was added to the wells and incubated for 1 h at room temperature (RT).
  • Wells were washed thrice with PBST and 10 10 phages per well of the HIV-1 GFPDL, diluted in blocking solution, were added for 2 h at RT. The unbound phages were removed in twelve washes with PBST followed by three washes with PBS.
  • Bound phages were eluted by addition of 0.1 N HCl containing BSA (1 mg/ml), for 10 min at RT, and neutralized by adding 8 ⁇ l of 2 M Tris solution per 100 ⁇ l eluate. Four rounds of affinity selection were carried out with each individual serum sample comprising the HIV seroconversion panel PRB-910.
  • phage clones enriched after four rounds of biopanning on each PRB-910 plasma sample were further screened for specific recognition by HIV seropositive sera and absence of reactivity with seronegative sera in affinity-capture phage ELISA.
  • the wells of ELISA plates (Immulon 2HB, Thermo Labsystems, Franklin, MA) were coated with 100 ng/well of anti-phage antibody (GE Healthcare, Piscataway, NJ), and blocked with DMEM/5% FBS. Subsequently, 10 10 phages of the selected clones were added per well and incubated for 1 h at RT.
  • Peptide sequences from Gag-p6 SEQ ID NO:3; 452- SRPEPTAPPAESFRFGEEITPTPSQKQEPKDKELYPPLASLRSLFGNDPSSQ-502) and gp41 cytoplasmic region (SK1; SEQ ID NO:50; 784- LIAARIVELLGHSSLKGLRRGWEALKYLWNLLQYWGQELKNSAISL- 829 and SK2; SEQ ID NO:55; 836 -AVAEGTDRVIEVVQRVCRAILNIPRRIRQGFERALL- 871) were chemically synthesized (amino acid residues are numbered based on the CON-OF-CONS alignment sequence in the Los Alamos database).
  • the optimal conditions for the p6 and gp41 ELISA were determined.
  • the p6 peptide was coated at 30 ng/100 ⁇ l/well while the gp41 peptides ( SEQ ID NO:50 and SEQ ID NO:55) were coated at 150 ng/100 ⁇ l/well each (total 300 ng/well) on Immulon-2HB plates.
  • PBST 20 mM PBS, 0.1% Tween-20
  • the unoccupied reactive sites were blocked by PBST containing 2% whole milk (2% WMPBST).
  • cut-off values were determined for p6 and gp41 peptides individually.
  • the cut-off values used are the average absorbance of Negative sera + 5 Standard Deviations (for each peptide). Specimens with an Absorbance / Cut-off ratios of ⁇ 1 are considered HIV-1 seropositive and those with ratios ⁇ 1 are considered HIV-1 seronegative.
  • HIV-1 seroconversion panels PRB-910, PRB-924, PRB-927, PRB-928, PRB-929, PRB-931 and mixed titer panel PRB-204 were purchased from SeraCare BioServices, (Gaithersburg, MD).
  • a seroconversion panel consists of plasma samples collected serially early after HIV-1 infection, and the virological and immunological profiles as assessed by commercial diagnostic kits for these plasma samples were provided by SeraCare BioServices. Additionally, twenty eight seroconversion panels were provided by the University of New South Wales (PHAEDRA Inventory, Sydney, Australia). HIV negative serum samples were obtained from National Institutes of Health Blood Bank and the Vaccine Research Center (VRC, NIAID, NIH, Bethesda, MD).
  • HVTN 203 (246 vaccinees and 78 placebos; conducted by the HIV Vaccine Trial Network)
  • RV124 conducted by the Walter Reed Army Institute of Research
  • VRC 004 40 vaccinees and 10 placebos
  • VRC 006 (30 vaccinees and 6 placebos
  • VRC 009 (9 vaccinees and no placebos) and VRC 010 were conducted by the Vaccine Research Center (NIAID, NIH)
  • VAX 003 and VAX 004 were conducted by VaxGen Inc.
  • the HIV infection status of a given sample was provided by the collaborating groups and also determined by in house testing using the BioRad HIV-1/2 plus O kit (Bio Rad laboratories, Woodinwille, WA). Samples obtained from VRC 009 and VRC 010 trials were also tested with the Capillus HIV-1/HIV-2 and Uni-Gold HIV rapid tests (Trinity Biotech, NY).
  • a gene-fragment phage display library (GFPDL) was constructed spanning the entire HIV-1 open reading frame of NL4-3.
  • the HIV-1 GFPDL contained more than 10 7 independent transformants.
  • PCR-based analysis and sequencing of the inserts confirmed that the library consisted of 100% recombinants, with an insert size of 50-300 bp, and random distribution across the HIV genome.
  • phages displaying sequences from the intracytoplasmic tail of gp41 were repeatedly recognized by antibodies from both early (1-6 months) and chronically infected individuals.
  • the cytoplasmic tail of gp41 was selected as the primary candidate for the differential assay as it is unlikely to be targeted by HIV-neutralizing antibodies, and it is not included in most HIV vaccines currently under development.
  • a p6 sequence was also selected, even though it was included in early generation HIV vaccines, it contains very few HLA restricted CTL epitopes ( Frahm, N. et al.
  • FIG. 7 Panels (a) and (b) demonstrate the binding of serially diluted representative plasma, PRB-204-06 (from SeraCare BioServices), in the p6 and gp41 ELISA, respectively. Multiple titrations with different samples demonstrated higher maximum reactivity with the gp41 peptides and a broader dynamic range when compared with the p6 peptide. Based on these analyses, all subsequent ELISA testing was conducted with 1:100 dilution of sera or plasma. The HIV infection status of a given sample was determined by licensed detection kits conducted either in-house or by an outside laboratory.
  • the reproducibility of the assay was determined by repeatedly testing nine HIV seropositive and three HIV seronegative samples from SeraCare BioServices. The distributions of the results obtained on multiple dates were evaluated for normality and the appropriate p-values were calculated using SigmaPlot. Representative plots are shown for one individual on the p6 and gp41 peptides ( Figure 7 , Panels (c) and (d), respectively. The upper and lower limits ( ⁇ 2SD) represent the 95% confidence intervals. Inter-assay variability was ⁇ 10% and intra-assay variability was ⁇ 5% for all the samples tested.
  • ELISA data for P6 and GP41 are shown as the ratio of test specimen absorbance to cut-off value. Ratios of 1.00 or greater are considered HIV seropositive and a sample ratio of less than 1 is considered HIV negative; for Abbott assays, PCR, and and FDA licensed EIA kits, HIV early seroconversion panels (within 6 weeks after HIV infection) and data for HIV RNA PCR quantification and FDA licensed serodiagnostic kits were provided by SeraCare BioServices, (Gaithersburg, MD).
  • the main proof-of-concept in support of the HIV-SELECTEST should come from evaluating the reactivity of vaccine induced antibodies in the course of prophylactic vaccine trials.
  • six blinded panels from completed vaccine trials (502 vaccinees) were tested including HVTN 203 (conducted by the HIV Vaccine Trial Network), RV124 (conducted by the Walter Reed Army Institute of Research) and VRC 004, VRC 006, VRC 009, and VRC 010 (conducted by the Vaccine Research Center, NIAID, NIH).
  • HVTN 203 conducted by the HIV Vaccine Trial Network
  • RV124 conducted by the Walter Reed Army Institute of Research
  • VRC 004, VRC 006, VRC 009, and VRC 010 conducted by the Vaccine Research Center, NIAID, NIH.
  • the description of the vaccine constructs used in the various trials and summary of the results obtained with the HIV-SELECTEST appear in Table 22 .
  • Canarypox vaccine constructs used in the RV124 and HVTN 203 contained the p6 epitope used in the new assay. Additionally, the protein boost in RV124 was gp160. In contrast, the vaccine constructs used in VRC 004 and VRC 006 lacked the peptide sequences used in the HIV-SELECTEST. Table 22 Summary of HIV-SELECTEST Reactivity with Vaccine Trial Samples Sponsor & Vaccine Trial Number Vaccine Composition Total No. of Samples Tested No. of HIV Infected Samples No.
  • the RV124 vaccine immunogens contained both the p6 & gp41 peptides used in the HIV-SELECTEST. 2.
  • the HVTN 203 vaccine immunogen contained the p6 but not the gp41 sequences used in HIV-SELECTEST. 3.
  • the VRC 004, 006, 009 vaccines did not contain either p6 or gp41 epitopes used in the HIV-SELECTEST, but participants in VRC 010 received p6-containing DNA (pGag) prune during VRC 007 phase I trial. 4.
  • Bio-Rad HIV-1/2+O ELA kit was used for sample screening. Seroconversion in VRC 009 and VRC 010 was determined by rapid tests. Capilius HIV-I/HIV-2 and Uni-Gold HIV. 5. Upon unblinding, these seropositive samples were confirmed is true HIV infections. 6.
  • VRC 004 had 10 placebo subjects and VRC 006 had 6 placebos, while VRC 009 and VRC 010 had no
  • the RV124 trial represents the worst case scenario, wherein all the peptide sequences used in the HIV-SELECTEST were part of either the priming or boosting immunogens. After the last boost (day 182), 80% of vaccinees strongly seroconverted in commercial HIV-1 detection kits even though none were HIV infected ( Table 22 and Table 20 ). However, only two individuals scored positive in the p6-ELISA, and none reacted in the gp41-ELISA. These findings suggested that the epitopes used in the HIV-SELECTEST were not very immunogenic in the context of the RV124 vaccine constructs.
  • the HVTN 203 blinded specimens included samples from pre-vaccination and four & six months post-vaccination obtained from 324 trial participants. In this panel, 30% of vaccinees seroconverted in the licensed HIV detection assays, while only 12% reacted with the p6 peptide in the HIV-SELECTEST ( Table 22 ). This finding was not surprising since the Canarypox/HIV prime (vCP1452) contained p6. Unexpectedly, two specimens were repeatedly reactive with gp41 even though these sequences were not in the vaccine constructs. However, after unblinding, it was confirmed that both samples were obtained from trial participants who got infected during this phase II trial.
  • VRC 004, VRC 006, VRC 009, and VRC 010 were conducted in 2002-2005.
  • the DNA plasmids (VRC 004) and non-replicating recombinant Adenovirus serotype 5 vector (rAd5) (VRC 006) express Gag-Pol-Nef (in VRC 004) or Gag-Pol (in VRC 006) and multi-clade (A, B, C) envelope genes (gp145 in the DNA vaccine and gp140 in the rAd5 vaccine).
  • rAd5 Adenovirus serotype 5 vector
  • VRC 009 and VRC 010 a subset of DNA vaccinated individuals (from VRC 004 and VRC 007 trials, respectively) was boosted with the rAd5/HIV vaccine.
  • the 4 weeks post-boost samples demonstrated a very significant increase in total HIV-specific antibodies (data not shown), and 100% seroconversion using two licensed rapid tests (Capillus HIV-1/HIV-2 and Uni-Gold HIV, Trinity Biotech, NY). Importantly, all vaccinees in these trials tested negative in the HIV-SELECTEST ( Table 22 ).
  • HIV-SELECTEST Specifically Detects Intercurrent HIV Infections During Multiple HIV Vaccine Trials Serum Sample Days After Estimated Date of HIV Infection 1 HIV-SELECTEST Vaccine Immunogen p6 gp41 HIVNET-1-1 -102.00 0.52 0.13 vCP205 +SF-2 rgp120 HIVNET-1-2 71 0.71 83.33 vCP205 + SF-2 rgp120 HIVNET-1-3 99 6.41 80.77 vCP205 + SF-2 rgp120 HIVNET-2-1 -158.00 0.22 0.30 vCP205 + Saline placebo HIVNET-2-2 24 11.19 0.13 vCP205 + Saline placebo HIVNET-2-3 87 11.74 88.83 vCP205 + Saline placebo HVTN 203-1-1 -22 0.32 0.13 vCP1452 mo(0,1,3,6) + AIDSVAX B/B mo(3,6) HVTN 203-1-2 16 15.78 0.10 vCP1452 mo(0,1,3,6) + AIDSVAX B/
  • Sequential samples soon after the first confirmed PCR positive visit were also obtained from 65 HIV infections during VAX 003 (AIDSVAX gp120 B/E) and 81 HIV infections during VAX 004 (AIDSVAX gp120 B/B') trials conducted by VaxGen.
  • the dates of PCR positivity and seroconversion by licensed HIV tests were provided by VaxGen.
  • Table 25 contains analysis of two representative HIV infections in VAX 003 and VAX 004 trials that developed strong reactivity to p6 and gp41 peptides.
  • the HIV-SELECTEST identified all intercurrent HIV infections within 90 days of PCR confirmation ( Figure 6 , Panels (b) and (c); Table 26 and Table 27 , for VAX 003 and VAX 004, respectively).
  • VAX 003 & VAX 004 Serum Sample Draw Date HIV PCR Analysis 1 HIV Seroconversion (EIA and WB) HIV-SELECTEST p6 gp41 VAX-003-9-1 02/02/00 + - 0.69 0.23 VAX-003-9-2 16102100 + + 7.49 2.13 VAX-003-9-3 09/03/00 + + 12.17 15.57 VAX-003-9-4 20/03/00 + + 14.42 70.4 VAX-003-9-5 18/04/00 + + 7.18 45.53 VAX-003-14-1 01/02/01 + - 4.05 0.23 VAX-003-14-2 15/02/01 + - 12.83 0.9 VAX-003-14-3 15/03/01 + + 8.21 12.33 VAX-003-14-4 12/04/01 + + 7.32 12.3 VAX-003-14-5 10/01/01 + + 6.56 13.17 VAX-004-9-1 17
  • VAX-004-10-2 4/11/2001 + + 0.07 16.56 VAX-004-11-1 10/23/1998 + - 0.19 0.44 VAX-004-11-2 11/3/1998 + - 0.23 1.33 VAX-004-11-3 11/18/1998 + + 0.18 4.37 VAX-004-12-1 11/2/2000 + - 0.09 1.37 VAX-004-13-1 2/11/2000 + - 0.06 0.11 VAX-004-13-2 8/10/2000 + + 0.05 87.08 VAX-004-14-1 9/13/2000 + - 1.97 1.63 VAX-004-14-2 9/27/2000 + + 1.81 38.40 VAX-004-15-1 1/25/2001 + - 0.03 0.11 VAX-004-15-2 2/8/2001 + - 0.12 0.22 VAX-004-15-3 7/11/2001 + + 0.02 8.72 VAX-004-16-1 2/22/2001 + - 0.59 0.19 VAX-004-16-2 3/8/2001 + - 0.45 0.19 VA
  • VAX-004-46-3 10/27/1999 + + 1.49 4.56 VAX-004-47-1 8/2/2000 + - 0.97 0.19 VAX-004-47-2 1/19/2001 + - 5.58 18.04 VAX-004-47-3 2/8/2001 + + 5.55 14.80 VAX-004-48-1 9/7/1999 + - 0.15 0.15 VAX-004-48-2 9/27/1999 + 0.14 0.48 VAX-004-48-3 2/8/2000 + + 0.16 37.04 VAX-004-49-1 11/14/2000 + - 0.09 0.20 VAX-004-49-2 12/5/2000 + + 3.11 0.78 VAX-004-50-1 11/7/2001 + - 0.08 0.22 VAX-004-50-2 11/21/2001 + - 0.73 0.52 VAX-004-50-3 12/18/2001 + + 1.67 88.28 VAX-004-51-1 12/14/1998 + - 0.51 0.19 VAX-004-51-2 12/28/1998 +
  • VAX-004-55-1 9/14/1999 + - 0.65 0.74 VAX-004-55-2 10/4/1999 + + 2.07 4.44 VAX-004-56-1 3/19/2001 + - 0.05 0.19 VAX-004-56-2 8/15/2001 + + 8.01 0.40 VAX-004-57-1 1/24/2002 + - 0.09 0.30 VAX-004-57-2 2/7/2002 + + 0.19 3.44 VAX-004-57-3 2/11/2002 + + 0.19 3.93 VAX-004-58-1 2/9/2000 + - 0.15 0.32 VAX-004-58-2 8/8/2000 + + 0.19 38.12 VAX-004-59-1 10/17/2001 + - 0.04 0.15 VAX-004-59-2 11/9/2001 + - 0.13 0.07 VAX-004-59-3 3/14/2002 + + 0.24 84.33 VAX-004-60-1 7/5/2001 + - 0.07 0.30 VAX-004-60-2 7/19/2001 + - 0.04 2.33
  • VAX-004-65-1 10/8/1999 + - 0.05 0.22 VAX-004-65-2 10/26/1999 + - 0.03 0.11 VAX-004-65-3 2/25/2000 + + 0.11 1.48 VAX-004-66-1 9/3/1999 + - 0.05 0.22 VAX-004-66-2 10/14/1999 + - 0.04 1.22 VAX-004-66-3 11/17/1999 + + 0.16 9.00 VAX-004-67-1 7/8/1999 + - 0.65 0.30 VAX-004-67-2 7/20/1999 + + 0.51 1.03 VAX-004-67-3 8/10/1999 + + 1.10 21.59 VAX-004-68-1 9/4/2001 + - 0.04 0.22 VAX-004-68-2 1/29/2002 + + 0.09 79.80 VAX-004-69-1 4/7/1999 + - 0.20 0.11 VAX-004-69-2 4/21/1999 + - 5.29 10.22 VAX-004-69-3 5/5/1999 + + 4.98 48.76 VAX
  • phage display library to clone and express the entire open reading frames of HIV afforded the opportunity to identify all the epitopes that are recognized by seroconversion antibodies during acute HIV infection.
  • Affinity selection of the phage display library using seroconversion panels led to the discovery of new epitopes in gp41 and p6, which were selected to develop a new differential diagnostic test.
  • the results described above demonstrate that vaccine generated antibodies scored either negative or weakly positive in the HIV-SELECTEST even when the p6 or gp41 sequences were part of the vaccine constructs (i.e., RV124 and HVTN 203). Furthermore, the HIV-SELECTEST detected all intercurrent HIV infections. It should be noted that while all intercurrent infections in the VAX 004 trial (conducted in the United States and the Netherlands) were with clade B viruses, all the HIV infections in the VAX 003 trial (conducted in Thailand), were with clade E variants, demonstrating the feasibility of using the HIV-SELECTEST outside the United States in a multiclade scenario, which is a prerequisite for global vaccine trials.
  • This inexpensive and high-throughput assay could be added to the algorithm of detection tests used in clinical sites and in blood and plasma collection centers. As such, this assay will be highly relevant for early diagnosis of intercurrent HIV infections in future vaccine trials, particularly in the setting of HIV vaccines that, while not able to prevent infection, may reduce viral loads after acquisition. Importantly, the HIV-SELECTEST should help to alleviate the concerns regarding social and economic harms due to long-term seroconversion of uninfected participants in preventive HIV vaccine trials.
  • Gag-p6-C-sub The sequence of the Gag-p6-C-sub peptide is provided below:
  • HIV detection assays may be conducted using the Gag-p6-C-sub ( SEQ ID NO:141 ) peptide alone, or in conjunction with any other peptide(s), etc., it is particularly preferred to combine the Gag p6-C-sub peptide ( SEQ ID NO:141 ) with peptides having the sequence of the consensus Gag-p6 ( SEQ ID NO:3 ) in the same ELISA plate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (13)

  1. Verfahren zum Nachweis der Gegenwart oder zur Messung der Konzentration eines Anti-HIV-1-Antikörpers in einer biologischen Probe eines Menschen, wobei das Verfahren die Ausführung eines Immunassays umfasst, der die folgenden Schritte umfasst:
    (a) Inkontaktbringen der biologischen Probe mit einer Peptidsequenz, die ein Epitop aufweist, das von dem Anti-HIV-1-Antikörper erkannt wird, wobei das Inkontaktbringen unter Bedingungen erfolgt, die ausreichen, um zu ermöglichen, dass der Anti-HIV-1-Antikörper bei Anwesenheit in der Probe zu dem Epitop bindet und einen Peptid-Anti-HIV-1-Antikörper-Komplex bildet;
    (b) Inkontaktbringen des gebildeten Peptid-Anti-HIV-1-Antikörper-Komplexes mit einem Anti-HIV-1-Antikörper-bindenden Molekül, wobei das Inkontaktbringen unter Bedingungen erfolgt, die ausreichen, um zu ermöglichen, dass das Anti-HIV-1-Antikörper-bindende Molekül zum Anti-HIV-1-Antikörper des gebildeten Peptid-Anti-HIV-1-Antikörper-Komplexes bindet und einen erweiterten Komplex bildet; und
    (c) Bestimmen der Gegenwart oder Konzentration des Anti-HIV-1-Antikörpers in der biologischen Probe durch Bestimmen der Gegenwart oder Konzentration des gebildeten erweiterten Komplexes;
    wobei das Peptid mindestens eine Aminosäuresequenz umfasst, die aus der Gruppe ausgewählt ist, die aus SEQ.-ID-Nr. 50-56 besteht.
  2. Verfahren nach Anspruch 1, wobei der Immunassay ein ELISA ist.
  3. Verfahren nach Anspruch 2, wobei der ELISA das Inkubieren der biologischen Probe in Gegenwart eines Feststoffträgers umfasst, wobei das Peptid an dem Träger immobilisiert ist, wobei der Träger mit Milch beschichtet ist, und wobei das Anti-HIV-1-Antikörper-bindende Molekül aus der Gruppe ausgewählt ist, die aus Anti-Human-IgG + IgM-Fc, Anti-Human-IgG-Fc, Anti-Human-IgG + IgM und Anti-Human-IgG besteht; wobei das Anti-HIV-1-Antikörper-bindende Molekül zu einem Enzym konjugiert ist.
  4. Verfahren nach Anspruch 1, wobei der Immunassay ein immunchromatographischer Assay ist.
  5. Verfahren nach Anspruch 4, wobei in dem immunchromatographischen Immunassay:
    in dem Schritt (a) die biologische Probe mit einem ersten porösen Träger in Kontakt gebracht wird, wobei der erste poröse Träger das Peptid enthält, wobei das Peptid nicht immobilisiert und nachweisbar markiert ist;
    in dem Schritt (b) der gebildete Peptid-Anti-HIV-1-Antikörper-Komplex mit einem zweiten porösen Träger in Kontakt gebracht wird, wobei der zweite poröse Träger mit dem ersten porösen Träger in Verbindung steht und ein immobilisiertes Anti-HIV-1-Antikörper-bindendes Molekül enthält; und
    in dem Schritt (c) die Gegenwart oder Konzentration des Anti-HIV-Antikörpers in der biologischen Probe durch Nachweisen der Gegenwart des markierten Peptids in dem zweiten porösen Träger bestimmt wird.
  6. Verfahren nach Anspruch 1, wobei das Epitop auf einem Peptid vorliegt, das die Aminosäuresequenz von SEQ.-ID-Nr. 50, SEQ.-ID-Nr. 51 oder SEQ.-ID-Nr. 55 aufweist.
  7. Verfahren nach Anspruch 6, wobei das Epitop auf einem Peptid vorliegt, das die Aminosäuresequenz von SEQ.-ID-Nr. 50 aufweist.
  8. Verfahren nach Anspruch 6, wobei das Epitop auf einem Peptid vorliegt, das die Aminosäuresequenz von SEQ.-ID-Nr. 51 aufweist.
  9. Verfahren nach Anspruch 6, wobei das Epitop auf einem Peptid vorliegt, das die Aminosäuresequenz von SEQ.-ID-Nr. 55 aufweist.
  10. Peptid, das die Aminosäuresequenz von SEQ.-ID-Nr. 50 oder SEQ.-ID-Nr. 55 aufweist.
  11. Immunologischer Komplex, der eine Peptidsequenz umfasst, die aus der Gruppe ausgewählt ist, die aus SEQ.-ID-Nr. 50-56 besteht, wobei das Peptid zu einem Anti-HIV-1-Antikörper gebunden ist, wobei der Anti-HIV-1-Antikörper zusätzlich zu einem Anti-HIV-Antikörper-bindenden Molekül gebunden ist, wobei das Peptid ein Epitop umfasst, das von dem Anti-HIV-1-Antikörper erkannt wird.
  12. Kit zum Nachweis der Gegenwart oder zur Messung der Konzentration eines Anti-HIV-1-Antikörpers in einer biologischen Probe eines Menschen, wobei der Kit Folgendes umfasst: ein hohles Gehäuse, das ein mehrschichtiges Filtersystem umfasst, und einen ersten und einen zweiten porösen Träger, wobei der zweite poröse Träger mit dem ersten porösen Träger in Verbindung steht und der erste poröse Träger mit dem mehrschichtigen Filtersystem in Verbindung steht, von dem ein Teil von dem Gehäuse zugänglich ist; wobei:
    der erste poröse Träger ein nicht immobilisiertes, markierte Peptid enthält, das mindestens eine Aminosäuresequenz umfasst, die aus der Gruppe ausgewählt ist, die aus SEQ.-ID-Nr. 50-56 besteht; wobei die Aminosäuresequenz ein Epitop umfasst, das von dem Anti-HIV-1-Antikörper erkannt wird; und
    der zweite poröse Träger einen immobilisierten, nicht markierten Antikörper enthält, der zu menschlichem IgG bindet.
  13. Kit nach Anspruch 12, wobei das Epitop auf einem Peptid vorliegt, das die Aminosäuresequenz von SEQ.-ID-Nr. 50, SEQ.-ID-Nr. 51 oder SEQ.-ID-Nr. 55 aufweist.
EP10174056.1A 2004-09-08 2005-09-02 Zusammensetzungen und verfahren zur detektion von hiv-1/hiv-2 infektion Active EP2309269B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60757904P 2004-09-08 2004-09-08
US67693105P 2005-05-03 2005-05-03
EP20050858397 EP1800126B1 (de) 2004-09-08 2005-09-02 Zusammensetzungen und verfahren für den nachweis von hiv-1/hiv-2-infektionen

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
EP20050858397 Division-Into EP1800126B1 (de) 2004-09-08 2005-09-02 Zusammensetzungen und verfahren für den nachweis von hiv-1/hiv-2-infektionen
EP20050858397 Division EP1800126B1 (de) 2004-09-08 2005-09-02 Zusammensetzungen und verfahren für den nachweis von hiv-1/hiv-2-infektionen
EP05858397.2 Division 2005-09-02

Publications (2)

Publication Number Publication Date
EP2309269A1 EP2309269A1 (de) 2011-04-13
EP2309269B1 true EP2309269B1 (de) 2016-10-26

Family

ID=37727749

Family Applications (4)

Application Number Title Priority Date Filing Date
EP20100174064 Withdrawn EP2295974A1 (de) 2004-09-08 2005-09-02 Zusammensetzungen und Verfahren zur Detektion von HIV-1/HIV-2 Infektion
EP20050858397 Active EP1800126B1 (de) 2004-09-08 2005-09-02 Zusammensetzungen und verfahren für den nachweis von hiv-1/hiv-2-infektionen
EP10174056.1A Active EP2309269B1 (de) 2004-09-08 2005-09-02 Zusammensetzungen und verfahren zur detektion von hiv-1/hiv-2 infektion
EP20100174062 Withdrawn EP2295973A1 (de) 2004-09-08 2005-09-02 Zusammensetzungen und Verfahren zur Detektion von HIV-1/HIV-2 Infektion

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP20100174064 Withdrawn EP2295974A1 (de) 2004-09-08 2005-09-02 Zusammensetzungen und Verfahren zur Detektion von HIV-1/HIV-2 Infektion
EP20050858397 Active EP1800126B1 (de) 2004-09-08 2005-09-02 Zusammensetzungen und verfahren für den nachweis von hiv-1/hiv-2-infektionen

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP20100174062 Withdrawn EP2295973A1 (de) 2004-09-08 2005-09-02 Zusammensetzungen und Verfahren zur Detektion von HIV-1/HIV-2 Infektion

Country Status (5)

Country Link
US (4) US7888003B2 (de)
EP (4) EP2295974A1 (de)
AU (1) AU2005335203A1 (de)
CA (1) CA2579676A1 (de)
WO (1) WO2007018550A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2421360B1 (de) 2009-04-22 2014-05-07 Lotus Bio (Nymphaea) Ltd. System zur trennung von spermien
EP2433132B1 (de) * 2009-05-21 2018-02-21 The U.S.A. as represented by the Secretary, Department of Health and Human Services Zusammensetzungen und verfahren zur detektion einer hiv-1/hiv-2-infektion
BR112012000189B1 (pt) * 2009-06-17 2020-01-21 3Shape As aparelho de varredura com foco.
CA2838091C (en) 2011-07-05 2019-08-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Hiv-1 genotyping assay for global surveillance of hiv-1 drug resistance
EP3276350B1 (de) 2012-06-22 2020-08-05 Bio-Rad Laboratories, Inc. Humaner faktor xiii als normalisierungskontrolle für immunoassays

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US627099A (en) * 1899-06-20 Fourth to thomas sterling
US559662A (en) * 1896-05-05 Japanning and enameling machine
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
JPS604422B2 (ja) 1976-10-07 1985-02-04 持田製薬株式会社 抗原の定量方法
IL51667A (en) 1977-03-16 1979-10-31 Miles Yeda Ltd Immunoassay for the determination of a hapten
NL7807532A (nl) 1978-07-13 1980-01-15 Akzo Nv Metaal-immunotest.
NL8000173A (nl) 1980-01-11 1981-08-03 Akzo Nv Toepassing van in water dispergeerbare, hydrofobe kleurstoffen als label in immunochemische testen.
US4401764A (en) 1980-02-07 1983-08-30 Technicon Instruments Corporation Immunoassays employing labeled reagent and a conjugate having two binding sites
GB2084317B (en) 1980-09-30 1984-01-18 Erba Farmitalia Antigen-linked competitive enzymeimmunoassay
US4661444A (en) 1984-03-29 1987-04-28 Ortho Diagnostic Systems Inc. Homogeneous immunoassays employing double antibody conjugates comprising anti-idiotype antibody
GB8422452D0 (en) 1984-09-05 1984-10-10 Serono Diagnostics Ltd Assay
CA1341482C (en) 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
US6534285B1 (en) 1984-12-24 2003-03-18 Genentech, Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
US4746631A (en) 1985-05-09 1988-05-24 Ultra Diagnostics Corporation Immunoassay method, device, and test kit
US6541609B2 (en) 1985-11-14 2003-04-01 President And Fellows Of Harvard College HIV-2 peptides
US5580739A (en) 1986-01-22 1996-12-03 Institut Pasteur Peptides of human immunodeficiency virus type 2 (HIV-2) and in vitro diagnostic methods and kits employing the peptides for the detection of HIV-2
US5830641A (en) 1986-01-22 1998-11-03 Institut Pasteur In vitro diagnostic assays for the detection of HIV-1 or HIV-2 employing viral-specific antigens and antibodies
US5585279A (en) 1986-01-23 1996-12-17 Davidson; Robert S. Time-resolved luminescence binding assays using a fluorescent transition metal label other than ruthenium
US5476765A (en) 1987-01-09 1995-12-19 United Biomedical, Inc. Synthetic peptide compositions with immunoreactivities to antibodies to HTLV and as vaccines
US5681696A (en) 1987-01-09 1997-10-28 United Biomedical, Inc. Synthetic peptide compositions with immunoreactivities to antibodies to HTLV
EP0310361A3 (de) 1987-09-30 1989-05-24 Beckman Instruments, Inc. Aus drei Verzahnungen bestehendes Konjugat und Verfahren zu seiner Verwendung
US5241047A (en) * 1988-12-08 1993-08-31 Biochem Pharma Inc. Synthetic peptides and mixtures thereof for detecting HIV antibodies
US5260189A (en) 1988-12-20 1993-11-09 Immunodiagnostics, Inc. Synthetic HIV-like peptides their compositions and uses
ATE116660T1 (de) 1989-01-13 1995-01-15 United Biomedical Inc Künstliche peptid-zusammensetzungen mit immunoreaktiven antikörpern von htlv-1.
US6589734B1 (en) 1989-07-11 2003-07-08 Gen-Probe Incorporated Detection of HIV
US5856088A (en) 1989-07-11 1999-01-05 Gen-Probe Incorporated Detection of human immunodeficiency virus type 1
US6008044A (en) 1989-08-24 1999-12-28 Bioclonetics Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1) and detection of antibodies against epitope (GCSGKLIC)
US5459060A (en) 1989-08-24 1995-10-17 Bioclonetics Incorporated Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1)
FI910245A (fi) 1990-01-24 1991-07-25 United Biomedical Inc Syntetiska peptidkompositioner med immunoreaktivitet mot htlv-antikroppar.
ES2089057T3 (es) 1990-07-18 1996-10-01 Abbott Lab Un reactivo sustituto de un analito para uso en metodos de ensayo de fijacion especifica, dispositivos y kits.
WO1992003579A1 (en) 1990-08-16 1992-03-05 Diagnostic Biotechnology, Inc. An augmented western blot format and immunoassay for detection of viral antibodies
US5571702A (en) 1991-03-29 1996-11-05 Genentech, Inc. Amplification method for detection of human PF4A receptors
US6352826B1 (en) 1991-11-25 2002-03-05 Yoreh Biotechnologies, Ltd. Method and kit for the detection of retroviral specific antibodies in seronegative individuals
ATE191791T1 (de) 1991-11-25 2000-04-15 Shiloov Medical Technologies L Verfahren für die bestimmung von antikörpern in seronegativen personen
EP0572737B1 (de) * 1992-06-04 2001-02-28 The Research Foundation For Microbial Diseases Of Osaka University Gag-Env Fusion-Antigen aus HIV
US5462852A (en) 1992-10-28 1995-10-31 The Government Of The United States Of America, As Represented By The Secretary, Dhhs HIV Nucleocapsid protein capture assay and method of use
US5891623A (en) 1992-11-09 1999-04-06 Consorzio Per Le Biotecnologie Diagnosis and treatment of AIDS onset
ATE178470T1 (de) 1993-02-10 1999-04-15 Reilly Daniel Joseph O Beutel zum spenden von fliessfähigen materialien
AU686616B2 (en) 1993-03-26 1998-02-12 Gen-Probe Incorporated Detection of human immunodeficiency virus type 1
US6074646A (en) 1993-10-26 2000-06-13 Board Of Regents, The University Of Texas System Nondenatured HIV envelope antigens for detecting early HIV-specific antibodies
US5563036A (en) 1994-04-29 1996-10-08 Tularik, Inc. Transcription factor-DNA binding assay
AU2587795A (en) 1994-05-20 1995-12-18 Tularik Inc. Epstein-barr virus transcription factor binding assay
US5747352A (en) 1994-05-23 1998-05-05 Beckman Instruments, Inc. Reagents and methods for the rapid and quantitative assay of pharmacological agents
JPH10502165A (ja) * 1994-05-31 1998-02-24 アボツト・ラボラトリーズ 合成ペプチド−改良イムノアッセイを使用する異なるｈｉｖ遺伝子型の検出
US5691147A (en) 1994-06-02 1997-11-25 Mitotix, Inc. CDK4 binding assay
US6429289B1 (en) 1994-06-23 2002-08-06 Massachusetts Institute Of Technology Class BI and CI scavenger receptors
US5627080A (en) 1994-07-29 1997-05-06 Beckman Instruments, Inc. Detergent-facilitated immunoassay for the rapid and quantitative assay of pharmacological agents
ES2293643T5 (es) * 1994-10-20 2012-02-02 Institut Pasteur Secuencias nucleotídicas de antígenos retrovíricos vih-1 del grupo (o subgrupo) o.
US5660979A (en) 1994-11-04 1997-08-26 Akzo Nobel N.V. Detection of human retrovirus infection
US5695930A (en) 1994-11-10 1997-12-09 Weinstein; David E. HIV test kit method for detecting anti-HIV-I antibodies in saliva
ATE184055T1 (de) 1995-01-27 1999-09-15 Us Gov Health & Human Serv Verfahren zum sensitiven nachweis von reverser transcriptase
US5599662A (en) 1995-02-17 1997-02-04 Hoffmann-La Roche Inc. Oliconucleotide primers and probes for the detection of HIV-1
US5843882A (en) 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
US5698411A (en) 1995-05-18 1997-12-16 Coulter Corporation Method for determining activity of enzymes in metabolically active whole cells
US5976822A (en) 1995-05-18 1999-11-02 Coulter International Corp. Method and reagent for monitoring apoptosis and distinguishing apoptosis from necrosis
US5759781A (en) 1995-12-22 1998-06-02 Yale University Multiparametric fluorescence in situ hybridization
US5961984A (en) 1996-04-02 1999-10-05 University Of Western Ontario Human T-cell lymphotropic virus type I envelope protein and human monoclonal antibodies specific therefor
US5939262A (en) 1996-07-03 1999-08-17 Ambion, Inc. Ribonuclease resistant RNA preparation and utilization
US6194221B1 (en) * 1996-11-19 2001-02-27 Wyntek Diagnostics, Inc. Hybrid one-step immunochromatographic device and method of use
US5876935A (en) 1997-01-08 1999-03-02 Dade Behring Inc. Luminescent specific binding assay
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
JP4776075B2 (ja) 1998-12-31 2011-09-21 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 改変ｈｉｖｅｎｖポリペプチド
ATE456677T1 (de) 1999-07-09 2010-02-15 Gen Probe Inc Hiv-1 detektion mittels nukleinsäureamplifizierung
US6586177B1 (en) 1999-09-08 2003-07-01 Exact Sciences Corporation Methods for disease detection
AU2001233063A1 (en) 2000-01-31 2001-08-07 Aaron Diamond Aids Research Center Vaccination of hiv infected persons following highly active antiretroviral therapy
US6582920B2 (en) 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
US7943146B2 (en) 2001-12-21 2011-05-17 Myrexis, Inc. Immunizing compositions comprising HIV-1 proviral constructs with an inactive p6 gag TSG101 UEV binding domain capable of producing budding-defective viral particles that remain tethered to the cell surface
US7101676B2 (en) * 2002-01-11 2006-09-05 Douglas Buechter Methods for identifying compounds which inhibit binding of nucleocapsid 7 protein to HIV-1 RNA
US20060115814A1 (en) * 2002-02-28 2006-06-01 Cloyd Miles W Methods and compositions, relating to hiv gp41 antigens and other hiv envelope antigens
DE10257770A1 (de) * 2002-12-10 2004-07-08 Ruprecht-Karls-Universität Heidelberg Expression von Peptiden des zytoplasmatischen Bereiches von HIV-gp41 zur Hemmung viraler Infektionen
ATE435425T1 (de) * 2003-09-11 2009-07-15 Idexx Lab Inc Verfahren zum nachweis des felinen immunschwächevirus
EP2371387A3 (de) 2003-09-17 2012-01-25 Duke University HIV Konsens / anzestrale Immunogene und deren Verwendung in Vakzinen
US8048431B2 (en) * 2003-09-17 2011-11-01 Duke University Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
EP2295974A1 (de) 2011-03-16
EP2309269A1 (de) 2011-04-13
US20090023164A1 (en) 2009-01-22
US8722324B2 (en) 2014-05-13
US20110201035A1 (en) 2011-08-18
EP1800126B1 (de) 2014-12-17
EP1800126A2 (de) 2007-06-27
US20110151436A1 (en) 2011-06-23
WO2007018550A3 (en) 2007-11-29
US20130143202A1 (en) 2013-06-06
AU2005335203A1 (en) 2007-02-15
US7888003B2 (en) 2011-02-15
WO2007018550A2 (en) 2007-02-15
EP2295973A1 (de) 2011-03-16
US9121855B2 (en) 2015-09-01
CA2579676A1 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
US9121855B2 (en) Method for the detection of HIV-1 antibodies utilizing a peptide containing a novel gp41 epitope
US9605030B2 (en) Rapid selection method for HIV gp-120 variants
Khurana et al. Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies
EP2433132B1 (de) Zusammensetzungen und verfahren zur detektion einer hiv-1/hiv-2-infektion
AU2012200790A1 (en) Compositions and methods for the detection of HIV-1/HIV-2 infection
AU2012200786A1 (en) Compositions and methods for the detection of HIV-1/HIV-2 infection
AU2012200789A1 (en) Compositions and methods for the detection of HIV-1/HIV-2 infection
US20060004184A1 (en) Method and device for detecting feline immunodeficiency virus
US20060002957A1 (en) Method and device for detecting feline immunodeficiency virus
Graham et al. Human Immunodeficiency Virus (HIV)
US20150218551A1 (en) Enhanced rapid immunogen selection method for hiv gp120 variants
Human JOHN W. GNANN, JR, AND MICHAEL BA OLDSTONE
Gnann Jr et al. Designing Peptides to Immunologically Distinguish Specific Human Immunodeficiency Virus Isolates
NZ614753B2 (en) Rapid selection method for hiv gp-120 variants

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100825

AC Divisional application: reference to earlier application

Ref document number: 1800126

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20121025

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160610

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 1800126

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 840383

Country of ref document: AT

Kind code of ref document: T

Effective date: 20161115

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602005050540

Country of ref document: DE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161026

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20161026

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 840383

Country of ref document: AT

Kind code of ref document: T

Effective date: 20161026

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161026

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161026

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161026

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161026

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170226

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161026

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161026

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161026

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170227

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161026

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602005050540

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161026

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161026

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161026

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161026

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161026

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170126

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161026

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20170727

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161026

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161026

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170902

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170930

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170902

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20050902

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161026

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161026

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230511

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230803

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230808

Year of fee payment: 19

Ref country code: DE

Payment date: 20230802

Year of fee payment: 19